Skip to content
Sunday, November 8, 2026
Epic Spin Online

{‘She lacks zero expertise’: this US healthcare community girds for Høeg's role at the Food and Drug Administration.

Given that the United States proceeds with historic revisions to its immunization schedules, one figure appears unexpectedly: Tracy Beth Høeg, a US-based sports medicine doctor and public health researcher who first made her name by casting doubt on coronavirus vaccines throughout the global health crisis and has concentrated on alleged fatalities after COVID-19 immunization in her brief time at the FDA.

Proposed Changes to Childhood Immunization Program

Public health authorities were set to announce major revisions to the childhood vaccine schedule earlier this month, synchronizing the US with the Danish national calendar, it is understood – a significant shift that would place the US out of step with much of the international standard with little proof for public health gain. This reveal has been postponed until the coming year.

Rather than the top vaccines chief, Tracy Beth Høeg is scheduled to present at the event. She was just designated temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this calendar year.

A Shift at the Regulatory Body

The acting appointment could signify a strengthened alliance between the drug and biologics centers as Høeg and Prasad consolidate power at the regulatory agency – and it signals a increased emphasis upon rolling back previously authorized vaccines at the FDA.

Dr. Høeg has repeatedly called for ending some pediatric shot schedules in the US to become more similar to the Danish model, a society with comprehensive healthcare and a population roughly the population of Wisconsin’s.

In her initial comments, she has kept her attention on vaccination policy – typically the purview of Dr. Prasad, director of the FDA’s vaccine center – as opposed to pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has no obvious track record in medication creation, oversight or leadership, which has been standard for former heads of the CBER. She has been employed at the FDA as a top consultant to the FDA chief and the vaccine center since earlier this year.

“She doesn’t seem to have any of the qualifications” for leading the pharmaceutical oversight division, stated Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in managing a sizeable institution. She has no expertise in drug approvals.”

Past heads of the center would “grasp laws and regulations and the science of pharmaceutical innovation”, said Janet Woodcock. “Frankly, she doesn’t have the kind of background that former directors who ran the center have had.”

This division has an enormous portfolio at the FDA, the former commissioner emphasized.

“The public just pays attention on the innovative therapies, but the generic drug division approves a multitude of generic drugs. There’s a biosimilars program, non-prescription drug unit and other areas, and every single one have to be looked after,” Dr. Woodcock noted. “The responsibility you don’t keep your eye on, that is precisely what that I always told people is going to bite you.”

Furthermore, a major leadership element to the position, which manages over 5,000 employees. “It’s a huge management job, if you do it right,” the former official concluded.

Official Statement and Controversial Initiatives

When asked about concerns about Høeg’s qualifications and whether this appointment indicates increased cooperation among regulatory chiefs on immunizations, a press secretary responded that the “inquiries rely on incorrect assumptions”.

“Her experience aligns with the functions of her position,” the representative stated, citing the time Dr. Høeg spent guiding the agency head on “medication safety and approval science, including computational safety modeling and shot safety tracking”.

As the temporary head, Høeg inherits the commissioner’s recently launched expedited review system, a contentious one-day drug-approval program that apparently concerned her preceding directors. “How are these therapies being chosen for this voucher program? Who makes the choices?” Howard asked. “There is a lot of lack of transparency going on at the FDA right now.”

In general, he remarked, “the agency looks to be trending towards laxer regulations of all drugs, aside from shots.”

Public History on Vaccines

With immunizations, Høeg has a more established, if concerning, track record, Howard said. She published a research paper using unconfirmed volunteer-provided data to assess the incidence of heart inflammation following Covid immunization. She counseled the Florida chief medical officer Dr. Joseph Ladapo, who reportedly have changed statistics to suggest COVID-19 vaccinations are pose a greater threat than they are.

Included in her “wish list” for the current federal leadership included revising rules for recently developed shots and discontinuing “unnecessary” vaccines, she stated post-election on a audio program. At the FDA, Dr. Høeg has according to sources proposed excluding adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who starts off with her beliefs and tailors the evidence to fit the evidence in a highly disingenuous, dishonest way,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg joined other skeptics, {like|

The writer

Gregory Espinoza

A tech enthusiast and digital strategist with over a decade of experience in analyzing emerging technologies and their impact on modern life.

Epic Spin Online

Type to search articles.